Equities Analysts Offer Predictions for Atara Biotherapeutics' Q1 2019 Earnings (ATRA)

Equities Analysts Offer Predictions for Atara Biotherapeutics' Q1 2019 Earnings (ATRA)

Investors sentiment decreased to 1.42 in Q4 2017. Narrowing in a bit closer, the 5 month price index is 2.94834, the 3 month is 1.80361, and the 1 month is now 0.86754.

Investors may be interested in viewing the Gross Margin score on shares of Atara Biotherapeutics, Inc. 12 funds opened positions while 25 raised stakes. One Trading Ltd Partnership holds 0% or 5,000 shs. (NYSE:PE). Pinnacle Assocs has 0.04% invested in Parsley Energy, Inc. Atara Biotherapeutics, Inc. (ATRA) has risen 88.73% since April 9, 2017 and is uptrending. (NASDAQ:ATRA) or 34 shs. Indexiq Advisors Ltd Liability accumulated 0.05% or 68,560 shares. Investors holded 26.16 million in 2017Q3 but now own 27.87 million shares or 6.54% more. If the ratio is greater than 1, then that means there has been an increase in price over the month. Citigroup downgraded the shares of ATRA in report on Thursday, February 15 to "Sell" rating. The stock's traded 0.36 million shares in session while it holds an average volume of 1 million shares.

Today, JPMorgan Chase initiated coverage on NASDAQ:ATRA - Atara Biotherapeutics (NASDAQ:ATRA) with a Overweight. (NASDAQ:ATRA) has 43% bullish analysts. Legal And General Group Public Ltd Com reported 6,326 shs. 12 West Capital Mgmt L P holds 0.87% or 398,700 shs in its capital. Credit Suisse Ag holds 19,072 shares. British Columbia Invest Mngmt has 157,325 shares for 0.03% of their portfolio. State Board Of Administration Of Florida Retirement Sys reported 102,563 shares. California State Teachers Retirement System now owns 42,159 shares of the biotechnology company's stock valued at $763,000 after buying an additional 1,836 shares during the last quarter. Bridger Management LLC now owns 2,598,599 shares of the biotechnology company's stock valued at $47,035,000 after buying an additional 946,086 shares during the last quarter. Royal Bancorporation Of Canada has invested 0% in Atara Biotherapeutics, Inc.

In other Atara Biotherapeutics news, CFO John Mcgrath sold 13,000 shares of the business's stock in a transaction that occurred on Friday, February 16th. Turner Heather D sold $464,210 worth of stock. Shares for $64,438 were sold by Ciechanover Isaac E. 6,000 Atara Biotherapeutics, Inc. Guggenheim assumed coverage on Atara Biotherapeutics in a research note on Thursday, March 15th. $900,815 worth of Atara Biotherapeutics, Inc. They set an "outperform" rating on the stock.

Analysts mean Recommendation on a stock is noted at 2.40. Therefore 50% are positive. Atara Biotherapeutics has a twelve month low of $11.80 and a twelve month high of $49.90. Moving averages can help spot trends and price reversals. Atara Biotherapeutics had 27 analyst reports since September 9, 2015 according to SRatingsIntel.

Facebook had lost almost 15 per cent following the initial Cambridge Analytica stories and Monday's closing price and was "probably oversold" heading into the hearing, said Bill Lynch, director of investment for Hinsdale Associates. Bank of New York Mellon Corp now owns 99,629 shares of the company's stock valued at $2,243,000 after buying an additional 17,195 shares in the last quarter. The stock of Atara Biotherapeutics, Inc. Granahan Investment Management Inc sold 86,415 shares as Bgc Partners Inc (BGCP)'s stock declined 12.13%. The firm has "Neutral" rating given on Wednesday, January 3 by Citigroup.

The stock increased 10.97% or $3.95 during the last trading session, reaching $39.95. About 355,359 shares traded. Vanguard invested 0% in Atara Biotherapeutics, Inc. JMP Securities lowered Atara Biotherapeutics from an "outperform" rating to a "market perform" rating in a research note on Wednesday, February 28th. The company reported ($0.88) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.78) by $0.10. Insiders sold 306,724 shares of company stock worth $11,207,924 over the last quarter. After $-1.15 actual earnings per share reported by Atara Biotherapeutics, Inc. for the previous quarter, Wall Street now forecasts -20.00 % EPS growth.

Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. The company has market cap of $1.55 billion. The Company's clinical stage T-cell product candidates include ATA129 that focuses on Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus associated post-transplant lymphoproliferative disorder after hematopoietic cell transplant and solid organ transplant; ATA188, which is in Phase I clinical trial for the treatment of multiple sclerosis; ATA520, a Phase I clinical trial product targeting cancers expressing the antigen Wilms tumor 1; and ATA230, which is Phase III clinical trials for refractory cytomegalovirus.now it has negative earnings.



Latest news

Xact Kapitalforvaltning AB Purchases New Stake in ON Semiconductor Corp (NASDAQ:ON)
Taking current value along prior value is a smoothing technique similar to that used in calculating an exponential moving average. Only utilities and real estate, which are sensitive to interest rates, posted losses. 1 indicates more volatile than the market.

Los Angeles Angels vs. Texas Rangers, 4-11
Sunday: Went 2 for 3, including a home run, drove in two runs and scored two in a 6-1 win over Oakland. Perez has gone 4-4 with a 3.27 ERA over 12 games, 11 of them starts, in his career versus the Angels .

Wisden's three women Cricketers of the Year have earned their awards
Only two women, Claire Taylor and Charlotte Edwards , had previously been included on the list since its 1889 inception. England's Heather Knight , Natalie Sciver and Anya Shrubsole are among Wisden's five Cricketers of the Year.

Amphenol Corp (NYSE:APH) Q4 2017 Sentiment
Amp Cap Investors Limited has invested 0.05% in Amphenol Corporation (NYSE: APH ). 16,345 are owned by Penobscot Investment Com. On Wednesday, July 26 the stock rating was maintained by Oppenheimer with "Buy". (NYSE:PPG) to report earnings on April, 19.

London’s Medical Startups Challenge Welcomes a New Judge, Max Polyakov
MBios is a joint project of Innovation House and the Ukrainian Medical Association of the United Kingdom (UMAUK). Such kind of challenges provides the participants with an opportunity to present their projects to the world.

Other news